Ozanimod: Sphingosine 1-phosphate receptors 1 and 5 (S1P1 and S1P5) modulator Treatment of multiple sclerosis Treatment of inflammatory bowel disease

Drugs of the Future

Volumn 40, Issue 9, 2015, Pages 575-581

  Gras, J ^a  

^a NONE   (Spain)

Author keywords

Multiple sclerosis; Ozanimod; RPC 1063; Sphingosine 1 phosphate receptor; Ulcerative colitis

Indexed keywords

OZANIMOD;

ARTICLE; ATRIOVENTRICULAR BLOCK; CYANATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84946565146     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2015.040.09.2387228     Document Type: Article

References (35)

1. Martinborough, E., Boehm, M.F., Yeager, A.R. et al. (Receptos, Inc.). Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis. US 8362048, US 2011172202, JP 2013510885, WO 2011060392, CN 102762100, KR 2012102704, EP 2498610.
2. Martinborough, E., Boehm, M.F., Yeager, A.R. et al. (Receptos, Inc.). Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith. WO 2015066515.
3. World Health Organization (2008). Atlas: Multiple Sclerosis Resources in the World 2008. Geneva: World Health Organization.
4. Chun, J., Brinkmann, V. A mechanistically novel, first oral therapy for multiple sclerosis: The development of fingolimod (FTY720 Gilenya). Discov Med 2011, 12(64): 213-28.
5. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385(9963): 117-71.
6. Berer, K., Krishnamoorthy, G. Microbial view of central nervous system autoimmunity. FEBS Lett 2014, 588(22): 4207-13.
7. Speight, R.A., Mansfield, J.C. Drug advances in inflammatory bowel disease. Clin Med 2013, 13(4): 378-82.
8. Abraham, C., Cho, J.H. Inflammatory bowel disease. N Engl J Med 2009, 361(21): 2066-78.
9. Modolecky, N.A., Soon, I.S., Rabi, D.M. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142(1): 46-54.
10. Ishii, I., Fukushima, N., Ye, X., Chun, J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004, 73: 321-54.
11. Kunkel, G.T., Maceyka, M., Milstein, S., Spiegel, S. Targeting the sphingo-sine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013, 12(9): 688-702.
12. Camm, J., Hla, T., Bakshi, R., Brinkmann, V. Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications. Am Heart J 2014, 168(5): 632-44.
13. A phase 3, multi-center, randomized, double-blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients (NCT2294058). ClinicalTrials.gov Web site. Accessed August 10, 2015.
14. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of oral RPC1063 as induction and maintenance therapy for moderate to severe ulcerative colitis (NCT02435992). ClinicalTrials.gov Web site. Accessed August 11, 2015.
15. Timony, G., Brooks, J., Powell, R. et al. The preclinical safety profile of RPC1063, a selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) agonist. Neurology [65th Annu Meet Am Acad Neurol (AAN) (March 16-23, San Diego) 2013] 2013, 80(Meeting Abstracts 1): Abst P01.158.
16. Peach, R., Brooks, J., Dedman, H., Powell, R., Scott, F., Timony, G. RPC1063, a potent and selective sphingosine 1-phosphate 1 receptor modulator, has a favourable preclinical safety profile. Mult Scler [29th Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 2-5, Copenhagen) 2013] 2013, 19(11 Suppl):Abst P375.
17. Clemons, B., Dedman, H., Powell, R., Martinborough, E., Timony, G., Peach, R.J., Scott, F.L. A small molecule S1P1 receptor agonist with significant efficacy in animal models of inflammatory bowel disease (IBD). Gastroenterology [Dig Dis Week (DDW) (May 19-22, San Diego) 2012] 2012, 142(5): Abst 358.
18. Brooks, J., Peach, R., Boehm, M. et al. RPC1063, a potent, selective S1P1 receptor modulator, is active in a therapeutic EAE model and exhibits favourable PK/PD properties in healthy volunteers. 28th Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 10-13, Lyon) 2012, Abst P915.
19. Scott, F.L., Timony, G., Brooks, J. et al. Metabolites of RPC1063 contribute to in vivo efficacy. Neurology [65th Annu Meet Am Acad Neurol (AAN) (March 16-23, San Diego) 2013] 2013, 80(Meeting Abstracts 1): Abst P05.157.
20. Receptos Publications. Receptos, Inc., http://ir.receptos.com/down-loads.cfm?view=all. Accessed August 6, 2015.
21. Scott, F.L., Behrens, E.- H.H., Clemons, B. et al. RPC1063 is a potent S1P1R agonist with efficacy in the SAMP1YitFc ileitis model: New evidence for dysregulation of S1P metabolism in preclinical models and patients with inflammatory bowel disease. Gastroenterology [Dig Dis Week (DDW) (May 18-21, Orlando) 2013] 2013, 144(5): Abst Tu1616.
22. Timony, G., Brooks, J., Hartung, J. et al. Pharmacokinetics and pharmaco-dynamics of RPC1063 and its metabolites in healthy adult volunteers. Neurology [66th Annu Meet Am Acad Neurol (AAN) (April 26-May 3, Philadelphia) 2014] 2014, 82(10, Suppl.): AbstP1.211.
23. Scott, F., Clemons, B., Dedman, H. et al. Pharmacokinetic properties of RPC1063, a selective S1P1and S1P5 receptor agonist, significantly contribute to efficacy in animal models of inflammatory bowel disease. 10th Congr Eur Crohn Colitis Org (ECCO) (February 18-21, Barcelona) 2015, Abst P032.
24. Brooks, J., Peach, R.J., Boehm, M. et al. RPC1063, a potent, selective S1P1 receptor modulator, is active in a therapeutic IBD model and exhibits favorable PK/PD properties in healthy volunteers. Gastroenterology [Dig Dis Week (DDW) (May 18-21, Orlando) 2013] 2013, 144(5): Abst Sa1221.
25. Hartung, J., Olson, A., Peach, R. et al. Results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist, in healthy adult volunteers. Mult Scler [29th Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 2-5, Copenhagen) 2013] 2013, 19(11 Suppl): Abst P983.
26. Hartung, J., Peach, R., Boehm, M. et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers. 28th Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 10-13, Lyon) 2012, Abst P457.
27. Olson, A., Hartung, J., Timony, G. et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor modulator, in healthy adult volunteers, results of a phase 1 study. Neurology [65th Annu Meet Am Acad Neurol (AAN) (March 16-23, San Diego) 2013] 2013, 80(Meeting Abstracts 1): Abst P01.178.
28. Olson, A., Timony, G., Hartung, J.P. et al. Results of a safety and tolerabil-ity study of RPC1063, a novel orally administered sphingosine-1-phosphate receptor 1 (S1p1r) agonist, in healthy adult volunteers. Gastroenterology [Dig Dis Week (DDW) (May 18-21, Orlando) 2013] 2013, 144(5):Abst Sa1222.
29. Olson, A., Hartung, J., Timony, G., Peach, R., Boehm, M., Smith, H., Gujrathi, S. Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist. 9th Congr Eur Crohn Colitis Org (February 20-22, Copenhagen) 2014, Abst P356.
30. Hartung, J., Olson, A., Peach, R. et al. Absence of a relevant effect on cardiac repolarization in a QT/QTc (TQT) study of RPC1063, a novel, selective S1P1 receptor agonist, in healthy adult volunteers. Neurology [66th Annu Meet Am Acad Neurol (AAN) (April 26-May 3, Philadelphia) 2014] 2014, 82(10, Suppl): Abst P2.229.
31. Cohen, J., Arnold, D.L., Comi, G. et al. Phase 2 results of the RADIANCE trial: A randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis. Mult Scler [Jt Triennial Congr Eur Am Commit Treat Res Multiple Scler (ECTRIMS/ACTRIMS) (September 10-13, Boston) 2014] 2014, 20(Suppl 1): Abst LB1.1.
32. Comi, G., Cohen, J., Arnold, D. et al. Efficacy results of the phase 2 portion of the RADIANCE trial: A randomized, double-blind, placebo-controlled trial of oral RPC1063 in adults with relapsing multiple sclerosis. Neurology [67th Annu Meet Am Acad Neurol (AAN) (April 18-25, Washington, D.C.) 2015] 2015, 84(14, Suppl.): Abst P7.198.
33. Selmaj, K., Arnold, D., Comi, G. et al. Safety and tolerability results of the phase 2 portion of the RADIANCE trial: A randomized, double-blind, placebo-controlled trial of oral RPC1063 in adults with relapsing multiple sclerosis. Neurology [67th Annu Meet Am Acad Neurol (AAN) (April 18-25, Washington, D.C.) 2015] 2015, 84(14, Suppl.): Abst P7.199.
34. Sandborn, W., Feagan, B., Wolf, D. et al. A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis: Results of the TOUCHSTONE study. 10th Congr Eur Crohn Colitis Org (ECCO) (February 18-21, Barcelona) 2015, Abst OP024.
35. A phase 2, multi-center, open-label induction trial with extension period to assess endoscopic improvement and changes in intestinal and serum bio-markers in patients with moderately to severely active Crohn's disease receiving oral ozanimod as induction therapy (NCT02531113). ClinicalTrials.gov Web site. Accessed September 23, 2015.